Xbiotech (XBIT) Stock
Small biotech developing new medicines through clinical research. Here's the price, business snapshot, and what's worth knowing about Xbiotech in July 2026.
XBIOTECH INC (ticker XBIT) is a small‑cap biotechnology company (market capitalisation roughly $79 million) focused on developing novel therapeutics through early‑stage research and clinical programmes. For investors, the key features are a pipeline‑led business model, high research and development intensity, and sensitivity to discrete clinical and regulatory milestones. Revenues may be limited or intermittent while programmes progress; value is often driven by trial readouts, partnerships or licensing deals. The company’s small size can mean higher stock volatility and lower trading liquidity compared with larger peers. Important risks include clinical failure, regulatory setbacks, cash burn and potential equity dilution if additional financing is required. This summary is educational only and not personal investment advice; investors should review the company’s filings, assess their own risk tolerance and consider seeking regulated advice. Biotech stocks can offer significant upside if research succeeds, but they also carry a meaningful chance of loss.
Stock Performance Snapshot
Financial Health
Xbiotech is showing solid financial performance with good cash flow and a strong book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring XBIT
Antiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.
Published: 16 November 2025
Explore BasketPharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: 5 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical trial readouts and regulatory milestones can meaningfully move valuation, though outcomes are uncertain and can be binary in nature.
Partnership Potential
Licensing or collaborations with larger pharma can de‑risk programmes and unlock value, while absent deals the company relies on internal funding.
High Volatility
Small market capitalisation and limited liquidity often lead to sharp price swings; suitable only for investors who accept higher risk and possible dilution.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
